Daily Equity Report 26 April 2019

1. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 DAILY EQUITY REPORT 26 THAPRIL 2019 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

2. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. Daily Equity Report INDIANFACE INDIAN MARKET CLOSE PREVIOUS ! INDIAN EQUITY BENCHMARK - Benchmark indices saw majorsellingpressureinlatetradeonApril25andreversed morethanhalfofpreviousday'sgains.TheBSESensexfell NIFTY 323.82pointsto38,730.86andtheNifty50dropped84.40 CLOSE PREVIOUS pointsto11,641.80amidrisingcrudeoilprices.Banking& NIKKEI financials pulled the market lower. Bharti Infratel (down 10.22 percent), Tata Steel (2.76 percent), Vedanta (2.49 percent), Indiabulls Housing Finance (2.11 percent) and 2190.50 2201.03 Hindalco(2.07percent)weretoplosers.UltraTechCement SECTORIAL INDICES and Grasim Industries rallied 5 percent each. BPCL, Dr CLOSE CHANGE (%) Reddy'sLabsandUPLwereothergainers. GLOBALFACE CNX 100 S&P CNX 500 9628.80 ! 4914.80 AsianMarket- Asianmarketsfinishedmixedasofthemost recentclosingprices.TheNikkei225gained0.48%,whilethe ShanghaiCompositeledtheHangSenglower.Theyfell2.43% CNX 200 6060.75 BANK NIFTY and0.87%respectively. TOP GAINERS ! U.S.Market– NorthandSouthAmericanmarketsfinished loweron WednesdaywithsharesinBrazilleadingtheregion. CLOSE ULTRACEMC 5.47 TheBovespaisdown0.92%whileMexico'sIPCisoff0.23% andU.S.'sS&P500islowerby0.22%. 4.82 ! 2.70 European markets – European markets are mixed. The DAX is higherby0.02%,whiletheFTSE100isleadingtheCAC40 BHARTIARTL 2.53 lower.Theyaredown0.27%and0.15%respectively. TOP LOSERS CLOSE CHANGE (%) -9.62 -2.71 -2.55 MARUTI -1.95 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

3. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. Daily Equity Report NIFTYSPOT MARKET MOVERS UPSIDE TREND STRATEGY SCRIPT CLOSE (%) 5.47 ULTRACEMC PIVOT POINTS 2.52 S3 11342 S2 11515 R1 11750 R2 11860 R3 12032 BPCL 11578 11687 2.27 S1-11502 S2-11412 R1-11765 R2-11863 0.90 TCS CLOSE (%) -9.62 INFRATEL -1.94 -1.93 -1.46 HDFC NET BUY (CR.) NET STRATEGY SELL ON RISE SELL (CR) PIVOT POINTS P 29710 5235.16 S1 29361 R1 29910 R2 R3 30808 28612 29161 30259 RESISTANCE DII 3181.77 BANK NIFTY NSE TOTALS ADVANCE S NIFTY BANK NIFTY Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

4. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. Daily Equity Report MARKET TALKS ! Chinese! DrReddysclarifieson regulatorsnod IPCALabacquiresRamdevChemicalfor Rs108.50cr IPCALab,initsfilingtotheexchanges,informedthatthe companyhasacquiredRamdevChemical(RCPL)forcash at Rs108.50cr. RCPL is engaged in the business of manufacturing and marketing of advanced drug intermediates, fine chemicals, moleculesandactivepharmaceuticalingredients(APls), thecompanysaidinapressnoteaftermarketshoursto theexchangeson Wednesday.Theacquisition ofRCPL willhelpthecompanytogrowitsAPIbusinessbyadding newmoleculesinitsproductsbasketwithpossibilityof forward integrating such products in its dosage formulationsbusinessfortheworldmarket,IPCAadded. Shares of Dr Reddys gained 3% on Thursday after the companyclarifiedthatitreceivedChineseregulatornod for anti-blood clotting drug. The company has received approval for the product Clopidogrel in China. "The companybelievesthatthesalesfromthisproductwillnot bematerialinthecurrentfinancialyeari.e.FY2020,"the company said in a press note on Thursday. The update comesaftertheexchangesoughtaclarificationfromthe companyonareportcarriedbyBusinessStandard,which stated that the company recently got an approval for a $1.6-billion anti-blood clotting drug from the Chinese regulatorafteran11-yearwait. custom synthesis ! MarutiSuzukiIndiadeclines2%asQ4FY19PAT drops4.6%yoy SharesofMarutiSuzukiIndiadeclined2%onThursday afterthecompanysPATforthefinalquarterofFY19 dropped4.6%yoytoRs1,795.6cr.Thecompanysrevenue forthequarterunderreviewrose1.4%yoyatRs21,459cr. MarginsforQ4FY19stoodat10.5%vs.14.2%ayearago. Further,EBITDAfell24.9%yoytoRs2,263.14crvs.Rs3, 015crayearago.Besides,thecompanysnetprofitforthe yearstoodatRs7,500.6cr,lowerby2.9%comparedtothe sameperiod inthepreviousyear. ! ZydusreceivesapprovalforLeflunomideTablets USP ZydusCadila,initspressnotetotheexchangesonThursday, informedthatthecompanyhasreceivedfinalapprovalfrom USFDAtomarketLeflunomideTabletsUSP(USRLD-Arava Tablets),10mgand20mg.Thecompanywillmanufacturethe drugatthegroupsformulationsmanufacturingfacilityatBaddi, Cadilasaidinapressnote.Thismedicationisusedtotreat rheumatoidarthritis,aconditionaffectingmultiplesmalland largejointsofthebody.Leflunomidebelongstoaclassof medications called disease-modifying antirheumatic drugs (DMARDS). Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

5. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. Daily Equity Report NAME OF THE STOCK : WIPRO DATE : 26/04/2019 SEGMENT : CASH CHART TYPE : Candlestick EXCHANGE : NSE TECHNICAL INDICATORS USED : VOLUME.MACD,RSI. CHART INVESTMENTADVICE: CALLCS CALL:- BUY WIPRO IN CASH ABOVE 295 TGT 300 SL 290 RATIONALEFORARRIVINGINVESTMENTADVICE: TECHNICALVIEW: THE STOCK TECHINCALLY IS UP ,TAKING SUPPORT OF VOLUME.RESISTANCE IS BROKEN TODAY WITH HEAVY VOLUME.AS WELL AS A POSSIBILITY OF UPWARD MOVEMENT IS THERE. OTHER REASON IF ANY :- SHOWING STRENGTHS IN INTRADAY CHARTS AS WELL. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

6. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. DISCLAIMER The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Capitalstars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk. Capitalstars Financial Research Private Ltd., Reserves all Rights. INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

7. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market. we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors. we provide intraday as well as delivery stock tips in NSE and BSE and commodity tips in MCX and NCDEX. Get our more services:- Intraday stock tips Financial advisory company Share market company Stock Tips * Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. * CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

8. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. BRANCH OFFICE Capitalstars Financial Research Private Limited PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME NO.54,VIJAYNAGAR INDORE REGISTERED OFFICE PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE Email:-backoffice@capiltalstars.in Contact us :- 9977499927, 9039012727 Report Is Checked by Investment Advisor: Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.